Loading clinical trials...
Loading clinical trials...
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With Primary-progressive Multiple Sclerosis Participating in the ORATORIO: a Post-hoc Analysis of a Double-blind, Randomized, Phase 3, Placebo-controlled Study
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Buffalo Neuroimaging Analysis Center
Buffalo, New York, United States
Start Date
October 1, 2023
Primary Completion Date
February 28, 2024
Completion Date
February 28, 2024
Last Updated
September 26, 2024
732
ACTUAL participants
Ocrelizumab
OTHER
Lead Sponsor
State University of New York at Buffalo
Collaborators
NCT07426991
NCT05893225
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions